Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
نویسندگان
چکیده
منابع مشابه
Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
Cisplatin, as the first-line anti-tumor agent, is widely used for treatment of a variety of malignancies including non-small cell lung cancer (NSCLC). However, the acquired resistance has been a major obstacle for the clinical application. Scutellarin is a active flavone extracted from Erigeron breviscapus Hand-Mazz that has been shown to exhibit anticancer activities on various types of tumors...
متن کاملphase ii study of gemcitabine and cisplatin in advanced non-small cell lung cancer
cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the efficacy and safety of gemcitabine and cisplatin combination. twentythree pati...
متن کاملHypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells
Hypoxia which commonly exists in solid tumors, leads to cancer cells chemoresistance via provoking adaptive responses including autophagy. Therefore, we sought to evaluate the role of autophagy and hypoxia as well as the underlying mechanism in the cisplatin resistance of lung cancer cells. Our study demonstrated that hypoxia significantly protected A549 and SPC-A1 cells from cisplatin-induced ...
متن کاملNucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
BACKGROUND In spite of the growing list of genetic abnormalities identified as being involved in DNA repair pathways that alter chemosensitivity in non-small-cell lung cancer (NSCLC) patients, translational assays have not yet been developed for use in individualized chemotherapy. METHODS In metastatic NSCLC, no single cisplatin-based chemotherapy regimen has been shown to be superior to any ...
متن کاملTRIB2 contributes to cisplatin resistance in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study focused on revealing Cisplatin-resistance mechanism(s) in this disease. Cisplatin-resistant SCLC ce...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Pharmacology
سال: 2018
ISSN: 1663-9812
DOI: 10.3389/fphar.2018.00092